Literature DB >> 12105349

Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients.

Mario Di Napoli1, Francesca Papa.   

Abstract

BACKGROUND AND
PURPOSE: The measurement of markers of inflammation or thrombosis has been proposed as a method to improve the prediction of risk in patients with vascular disease. We evaluated the usefulness of these markers as predictors of cardiovascular events in ischemic stroke patients.
METHODS: We analyzed levels of C-reactive protein (CRP), fibrinogen, and D-dimer within the first 24 hours after stroke onset in 473 first-ever ischemic stroke patients and determined the cumulative survival curves free of cardiovascular events in relation to the level of each of these markers according to the Kaplan-Meier method. We adjusted for possible confounding variables using a multivariate Cox proportional-hazards model.
RESULTS: Patients in the highest tertiles of D-dimer, fibrinogen, and CRP were associated with an excess risk of new cardiovascular events of 36% (P=0.0134), 63% (P<0.0001), and 72% (P<0.0001), respectively, compared with patients in the lowest tertile. The patients in the highest tertile of CRP had 4 times the risk (hazard ratio, 4.04; P<0.0001) of a new cardiovascular event. Smoking, age, sex, and body mass index did not modify risk, and risk was independent of other confounding variables and of D-dimer and fibrinogen levels. The use of ticlopidine was associated with a significant risk reduction among patients with lower (86%, P=0.0159) and middle (69%, P<0.0001) levels of CRP, whereas a nonsignificant excess risk (27%, P=0.3896) was evident among those with the highest levels.
CONCLUSIONS: Elevated levels of CRP, more than of D-dimer and fibrinogen, are related to the risk of new cardiovascular events after ischemic stroke. The efficacy of antiplatelet therapy in secondary prevention appears to be directly related to level of inflammatory and thrombotic markers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12105349     DOI: 10.1161/01.str.0000019124.54361.08

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  30 in total

1.  Role of anti-infective strategies in the prevention of stroke.

Authors:  Armin J Grau
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-07

Review 2.  Inflammation, Autoimmunity, Infection, and Stroke: Epidemiology and Lessons From Therapeutic Intervention.

Authors:  Neal S Parikh; Alexander E Merkler; Costantino Iadecola
Journal:  Stroke       Date:  2020-02-12       Impact factor: 7.914

3.  Hyperfibrinogenemia and functional outcome from acute ischemic stroke.

Authors:  Gregory J del Zoppo; David E Levy; Warren W Wasiewski; Arthur M Pancioli; Andrew M Demchuk; James Trammel; Bart M Demaerschalk; Markku Kaste; Gregory W Albers; Eric B Ringelstein
Journal:  Stroke       Date:  2009-03-19       Impact factor: 7.914

4.  A preliminary method development study to identify potential stroke biomarkers in plasma using multiple chromatographies with nanoLC-ESIMS detection.

Authors:  Phanichand Kodali; Julio A Landero-Figueroa; Joseph Caruso; Opeolu Adeoye
Journal:  J Neural Transm (Vienna)       Date:  2013-04-13       Impact factor: 3.575

5.  C-reactive protein and aetiological subtypes of cerebral infarction.

Authors:  Alessandro Terruzzi; Laura Valente; Roberto Mariani; Luca Moschini; Massimo Camerlingo
Journal:  Neurol Sci       Date:  2008-09-20       Impact factor: 3.307

Review 6.  Peripheral polymorphonuclear leukocyte activation as a systemic inflammatory response in ischemic stroke.

Authors:  Xiaoye Mo; Ting Li; Guang Ji; Wei Lu; Zhiping Hu
Journal:  Neurol Sci       Date:  2013-04-26       Impact factor: 3.307

7.  Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.

Authors:  Boris Leithäuser; Jai-Wun Park
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

8.  Serum interleukin-6 soluble receptor in relation to interleukin-6 in stroke patients.

Authors:  Tomasz Dziedzic; Elzbieta A Gryz; Wojciech Turaj; Agnieszka Slowik; Andrzej Szczudlik
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 9.  Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke.

Authors:  Charles C Esenwa; Mitchell S Elkind
Journal:  Nat Rev Neurol       Date:  2016-09-12       Impact factor: 42.937

Review 10.  Magnesium in stroke treatment.

Authors:  K W Muir
Journal:  Postgrad Med J       Date:  2002-11       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.